The priinary aim of the M.D. Ancierson Cancer Center Leukemia SPORE is to improve the treatment of patients with leukemia. A fundamental component to meeting this objective is the conduct of focused translational research involving human tissue and blood specimens, allowing investigation of the biology of target and normal tissues, evaluation of treatment effects on both target and normal tissue, and modulation of, relevant biomarkers. The Pathology and Tissue Core will collect, process, and maintain human tissue specimens from patients and m distribute these tissues to the Leukemia SPORE investigators. The Pathology and Tissue Core has the following aims: 1. Develop and maintain a repository of intact cells, serum, DNA, RNA, and protein derived from blood and bone marrow specimens obtained from patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. Samples are collected and processed at the time of diagnosis and during/after therapy with SPORE-associated clinical protocols, while in remission or at relapse. The Core will distribute tissue specimens to the Leukemia SPORE investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within Leukemia SPORE projects. The Core will provide comprehensive hematopathologic characterization of the samples used in Leukemia SPORE projects. 2. Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukeiTiia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. 3. Facilitate inter-leukemia SPORE and extra-leukemia SPORE collaborations through sharing of blood and marrow resources. Over the past 9 years of funding, the Core has fulfilled its mission of providing samples to all Leukemia SPORE projects, as well as outside investigators'requests. In the current funding period (2008-2011), we have distributed 10,278 vials of material to 95 requests to SPORE researchers as well as leukemia researchers outside the SPORE.

Public Health Relevance

Research into leukemia depends on the availability of leukemic samples obtained from patients. These leukemic cells are used to make DNA, RNA and protein, which are used to identify the characteristics of the disease and viable cells which are used to test how leukemic cells respond to stimulation, or potential new therapies. This Core provides the patient samples that are key to understanding and curing leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-11
Application #
8499754
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2013-05-01
Project End
2018-08-31
Budget Start
2013-09-13
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$129,052
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Zhang, Hanghang; Pandey, Somnath; Travers, Meghan et al. (2018) Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell 175:1244-1258.e26
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903

Showing the most recent 10 out of 487 publications